Trade Bristol Myers BMY

BristolMyers live chart

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BristolMyers News

number1 2025 Dec 05, 00:01

Pimco's Triumph in 2025: A Bold Bond Strategy Pays Off

number1 2025 Dec 04, 00:00

Fed Independence on the Line? Political Influence in 2026

number1 2025 Dec 04, 00:00

US Holiday Shopping Season: Record Online Sales Amid Economic Vulnerabilities

number1 2025 Dec 03, 00:00

US Economic Outlook 2026: A Roubini Analysis

number1 2025 Dec 02, 00:01

Fed's Divergent Votes: A Sign of Policy Uncertainty?

Frances Wang 2024 Dec 29, 16:00

Trading wisdom: how can I improve myself as a trader?

Frances Wang 2024 Dec 26, 16:00

Can you trade CFDs on crypto: platform to trade cryptocurrency CFDs

Frances Wang 2024 Dec 25, 16:00

EQV stock price today: Is EQV Ventures a good investment?

Frances Wang 2024 Dec 25, 16:00

How to start investing in dividend ETFs: 7 Dividend ETFs to Watch

Frances Wang 2024 Dec 23, 16:00

TSLQ ETF price forecast: How to track TSLQ ETF prices?

Latest news

Show more
number1 2026 Mar 14, 00:00

Russia Reportedly Providing Intelligence Support to Iran Amidst Escalating Middle East Conflict

number1 2026 Mar 14, 00:00

US Economic Signals: Inflation Concerns and Growth Challenges

number1 2026 Mar 14, 00:00

Gold Market Analysis: Navigating Stability Amidst Escalating Geopolitical Tensions

number1 2026 Mar 14, 00:00

Apple Slashes App Store Commissions in China for Developers

number1 2026 Mar 14, 00:00

Geopolitical Tensions, Economic Crosscurrents, and Technological Advancements: A Forward-Looking Analysis

number1 2026 Mar 13, 12:07

Aussie Dollar Sees Surge in Bullish Bets Ahead of Reserve Bank of Australia Rate Decision

number1 2025 Dec 06, 00:00

India's Silver Demand Surge: New Loan Framework Boosts Market

number1 2025 Dec 04, 00:00

ADP Employment Data and the Fed's Policy Path: A Closer Look

Info

Spread

0.41

Spread (%)

0.6157 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Tuesday

13:31 - 19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

128405045248

Shares Outstanding

2042714656

Earnings Date (Next)

2001-08-07

Div Yield

2026-11-02

Ex-Dividend Date

2026-10-02

Forward annual dividend rate

2.52

Forward annual dividend yield

0.041

EPS

4.54

Learn more about this instrument

Bristol Myers Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Related Instruments

Asset
Sell
Buy
Change (%)
View all instruments

Latest Education Articles

Show more
Trustpilot